The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Duration of Humoral Immunity to Common Viral and Vaccine Antigens
Open accessAbstract
BACKGROUND: Maintenance of long-term antibody responses is critical for protective immunity against many pathogens. However, the duration of humoral immunity and the role played by memory B cells remain poorly defined. METHODS: We performed a longitudinal analysis of antibody titers specific for viral antigens (vaccinia, measles, mumps, rubella, varicella-zoster virus, and Epstein-Barr virus) and nonreplicating antigens (tetanus and diphtheria) in 45 subjects for a period of up to 26 years. In addition, we measured antigen-specific memory B cells by means of limiting-dilution analysis, and we compared memory B-cell frequencies to their corresponding serum antibody levels. RESULTS: Antiviral antibody responses were remarkably stable, with half-lives ranging from an estimated 50 years for varicella-zoster virus to more than 200 years for other viruses such as measles and mumps. Antibody responses against tetanus and diphtheria antigens waned more quickly, with estimated half-lives of 11 years and 19 years, respectively. B-cell memory was long-lived, but there was no significant correlation between peripheral memory B-cell numbers and antibody levels for five of the eight antigens tested. CONCLUSIONS: These studies provide quantitative analysis of serologic memory for multiple antigens in subjects followed longitudinally over the course of more than one decade. In cases in which multiple exposures or repeated vaccinations were common, memory B-cell numbers did not correlate with antibody titers. This finding suggests that peripheral memory B cells and antibody-secreting plasma cells may represent independently regulated cell populations and may play different roles in the maintenance of protective immunity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is likely that longer-term follow-up studies will reveal a further slowing of decay, with titres reaching a stable level analogous to humoral responses to other viral pathogens22,23.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [23]
In the citing paper
“Previous work has found that antibodies and memory B cells correlate for some vaccines or antigens, but do not correlate for many others (34).”
From Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination (2021) · cites this paper as [34]
In the citing paper
“We focused on the RBD since it is the target of the majority of the more potent SARS-CoV-2 neutralizing antibodies discovered to date21–26.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [21]
In the citing paper
“Class 1 and 2 antibodies are among the most potent and also the most abundant antibodies7,8,21,22,25,39.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [21]
In the citing paper
“The vaccines elicit antibody responses against the RBD, the major target of neutralizing antibodies21–26, in a manner that resembles natural infection.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [21]
Citations
Cites
Adjusting for multiple testing—when and how?
Bender, R., & Lange, S. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00314-0 · Cited by 3,168
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Immunological memory and protective immunity: understanding their relation
Ahmed, R., & Gray, D. (1996) · Science · doi:10.1126/science.272.5258.54 · Cited by 1,775
Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells
Bernasconi, N. L., Traggiai, E., & Lanzavecchia, A. (2002) · Science · doi:10.1126/science.1076071 · Cited by 1,304
Humoral Immunity Due to Long-Lived Plasma Cells
Slifka, M. K., Antia, R., Whitmire, J. K., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80541-5 · Cited by 1,249
Self-citationCompetence and competition: the challenge of becoming a long-lived plasma cell
Radbruch, A., Muehlinghaus, G., Luger, E., Inamine, A., Smith, K. G. C., Dörner, T., & Hiepe, F. (2006) · Nature reviews. Immunology · doi:10.1038/nri1886 · Cited by 1,033
Duration of antiviral immunity after smallpox vaccination
Hammarlund, E., Lewis, M. W., Hansen, S. G., Strelow, L. I., Nelson, J. A., Sexton, G. J., Hanifin, J. M., & Slifka, M. K. (2003) · Nature Medicine · doi:10.1038/nm917 · Cited by 946
Self-citationLifetime of plasma cells in the bone marrow
Manz, R. A., Thiel, A., & Radbruch, A. (1997) · Nature · doi:10.1038/40540 · Cited by 866
Cutting edge: long-term B cell memory in humans after smallpox vaccination
Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L., & Ahmed, R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.4969 · Cited by 695
Measles Antibody: Reevaluation of Protective Titers
Chen, R. T., Markowitz, L. E., Albrecht, P. G., Stewart, J. A., MOFENSON, L. M., Preblud, S. R., & Orenstein, W. A. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/162.5.1036 · Cited by 606
Flagged first, then by citations
Research works printed but not linked: 3
- Bojlen K, 1955, Dan Med Bull, 2, 70
- Wolters KL, 1942, Zeitschrift fur Hyeitschrift, 124, 326
- Slifka MK. Mechanisms of antiviral immunity: studies on recombinant Listeria monocytogenes as a vaccine for inducing protective CTL memory and analysis of long-term antibody production after acute LCMV infection. Los Angeles: University of California, Los Angeles, 1996 (dissertation).
Cited by
Sorted by citations
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,927
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Expanding roles for CD4+ T cells in immunity to viruses
Swain, S. L., McKinstry, K. K., & Strutt, T. M. (2012) · Nature reviews. Immunology · doi:10.1038/nri3152 · Cited by 1,011
Metadata
- Authors
- Amanna, I. J., Carlson, N. E., & Slifka, M. K.
- Affiliations
- Oregon Health & Science University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-08
- Volume
- 357
- Issue
- 19
- Pages
- 1903-1915
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2128666074
- Cited by
- 1,286
- References
- 38
- Citations by year
- 2026: 60 · 2025: 81 · 2024: 82 · 2023: 72 · 2022: 103 · 2021: 127 · 2020: 73 · 2019: 60 · 2018: 64 · 2017: 64 · 2016: 52 · 2015: 47 · 2014: 68 · 2013: 67 · 2012: 66
- FWCI
- 17.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P01AG023664)
- National Center for Research Resources (RR000163, P51RR000163, M01RR000334, UL1RR024140, RR024140, RR 000334)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- humoral immunity, antibody half-life, memory B cells, long-term antibody persistence, vaccine antigens, measles, mumps, rubella, varicella-zoster virus, Epstein-Barr virus, tetanus toxoid, diphtheria toxoid, protective immunity
- MeSH terms
- Adult, Aging, Antibodies, Bacterial, Antibodies, Viral, Antibody Formation, Antigens, Bacterial, Antigens, Viral, B-Lymphocytes, Diphtheria, Female, Half-Life, Humans, Longitudinal Studies, Male, Middle Aged, Plasma Cells, Tetanus, Time Factors, Vaccines, Virus Diseases, Seroepidemiologic Studies, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
